Stott, David J; Rodondi, Nicolas; Kearney, Patricia M; Ford, Ian; Westendorp, Rudi GJ; Mooijaart, Simon P; Sattar, Naveed; Aubert, Carole E; Aujesky, Drahoimir; Bauer, Douglas C; +37 more... Baumgartner, Christine; Blum, Manuel R; Browne, John P; Byrne, Stephen; Collet, Tinh-Hai; Dekkers, Olaf M; den Elzen, Wendy PJ; Du Puy, Robert S; Ellis, Graham; Feller, Martin; Floriani, Carmen; Hendry, Kirsty; Hurley, Caroline; Jukema, J Wouter; Kean, Sharon; Kelly, Maria; Krebs, Danielle; Langhorne, Peter; McCarthy, Gemma; McCarthy, Vera; McConnachie, Alex; McDade, Mairi; Messow, Martina; O’Flynn, Annemarie; O’Riordan, David; Poortvliet, Rosalinde KE; Quinn, Terence J; Russell, Audrey; Sinnott, Carol; Smit, Jan WA; Van Dorland, H Anette; Walsh, Kieran A; Walsh, Elaine K; Watt, Torquil; Wilson, Robbie; Gussekloo, Jacobijn; TRUST Study Group; (2017) Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. The New England journal of medicine, 376 (26). pp. 2534-2544. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa1603825

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4645449/

DOI: https://doi.org/10.1056/NEJMoa1603825

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Copyright the publishers
The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Stott at the Glasgow Royal Infirmary, Room 2.42, 2nd Fl., New Lister Building, Glasgow G31 2ER, United Kingdom, or at david.j.stott@glasgow.ac.uk.

*A complete list of the investigators in the Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism — A Randomized Placebo Controlled Trial (TRUST) is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on April 3, 2017, at NEJM.org.

N Engl J Med 2017;376:2534-44. DOI: 10.1056/NEJMoa1603825

BACKGROUND

The use of levothyroxine to treat subclinical hypothyroidism is controversial. We aimed to determine whether levothyroxine provided clinical benefits in older persons with this condition.

METHODS

We conducted a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults who were at least 65 years of age and who had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range). A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment. The two primary outcomes were the change in the Hypothyroid Symptoms score and Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year (range of each scale is 0 to 100, with higher scores indicating more symptoms or tiredness, respectively; minimum clinically important difference, 9 points).

RESULTS

The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women. The mean (±SD) thyrotropin level was 6.40±2.01 mIU per liter at baseline; at 1 year, this level had decreased to 5.48 mIU per liter in the placebo group, as compared with 3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 μg. We found no differences in the mean change at 1 year in the Hypothyroid Symptoms score (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group; between-group difference, 0.0; 95% confidence interval [CI], −2.0 to 2.1) or the Tiredness score (3.2±17.7 and 3.8±18.4, respectively; between-group difference, 0.4; 95% CI, −2.1 to 2.9). No beneficial effects of levothyroxine were seen on secondary-outcome measures. There was no significant excess of serious adverse events prespecified as being of special interest.

CONCLUSIONS

Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism. (Funded by European Union FP7 and others; TRUST ClinicalTrials.gov number, NCT01660126.)
**Subclinical Hypothyroidism** is defined as an elevated serum thyrotropin level and a serum free thyroxine level within the reference range. Between 8% and 18% of adults 65 years of age or older have these biochemical features, and the prevalence is higher among women than among men.

Subclinical hypothyroidism is a possible contributor to many problems in older persons. Thyroid hormones have multiple effects, since they act as an essential regulatory factor in numerous physiological systems, including the vascular tree and the heart, the brain (including cognition), skeletal muscle, and bone. Tiredness is the most important symptom of overt hypothyroidism, but most patients with subclinical hypothyroidism have no symptoms or have nonspecific symptoms. There is a convincing epidemiologic association with subsequent coronary heart disease.

Randomized, controlled trials of levothyroxine replacement for the treatment of subclinical hypothyroidism have been small and have yielded only limited evidence regarding the possible benefits and risks of treatment. We aimed to determine whether there are clinical benefits from levothyroxine replacement in older persons with subclinical hypothyroidism.

**METHODS**

**Trial Overview**

The trial protocol, which was published previously and is available with the full text of this article at NEJM.org, was approved by the relevant ethics committees and regulatory authorities in all the countries involved in the trial. Participants provided written informed consent.

The trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The Robertson Centre for Biostatistics at the University of Glasgow was the trial data and biostatistics center.

The European Union FP7 provided primary financial support for the conduct of the trial. Supplies of levothyroxine and matching placebo were provided free of charge by Merck (Darmstadt, Germany). The funder, the trial sponsors (NHS Greater Glasgow and Clyde Health Board and University of Glasgow, United Kingdom; University College Cork, Ireland; Leiden University Medical Center, the Netherlands; and University of Bern and Bern University Hospital, Switzerland), and Merck played no role in the design, analysis, or reporting of the trial. The main sponsor (NHS Greater Glasgow and Clyde Health Board) contributed to the writing of the protocol. None of the sponsors had any involvement in the analysis or the reporting of the results. The authors vouch for the accuracy and completeness of the data and analyses reported and for the fidelity of the trial to the protocol.

**Participants**

Participants were identified from clinical laboratory and general practice databases and records. The inclusion criteria were an age of 65 years or more and persistent subclinical hypothyroidism, defined as an elevated thyrotropin level (4.60 to 19.99 mIU per liter) that was measured on at least two occasions that were 3 months to 3 years apart, with the free thyroxine level within the reference range. The main exclusion criteria for the trial were a current prescription for levothyroxine, antithyroid drugs, amiodarone, or lithium; thyroid surgery or receipt of radioactive iodine within the previous 12 months; dementia; hospitalization for a major illness or an elective surgery within the previous 4 weeks; an acute coronary syndrome (including myocardial infarction or unstable angina) within the previous 4 weeks; and terminal illness.

**Trial Design and Regimen**

We conducted a randomized, double-blind, parallel-group trial of levothyroxine versus placebo. Patients underwent randomization in a 1:1 ratio, with stratification according to country, sex, and starting dose, with the use of randomly permuted blocks.

The active intervention started with levothyroxine at a dose of 50 μg daily (or 25 μg in patients with a body weight of <50 kg or with known coronary heart disease [previous myocardial infarction or symptoms of angina pectoris]) or matching placebo. Dose adjustment in the levothyroxine group was aimed to result in a thyrotropin level within the reference range (0.40 to 4.59 mIU per liter). Details regarding how the dose was adjusted and the mock adjustment in the placebo group are provided in the Supplementary Appendix, available at NEJM.org. All dose adjustments were generated and executed by means of computer without the intervention of a physician. The participants, investigators, and...
treated physicians were unaware of the results of thyrotropin measurements throughout the course of the trial.

**PROCEDURES AND OUTCOMES**

The two primary outcomes for the trial were the change from baseline to 12 months in the Thyroid-Related Quality-of-Life Patient-Reported Outcome measure (ThyPRO) Hypothyroid Symptoms score (4 items) and Tiredness score (7 items); each scale ranges from 0 to 100, with higher scores indicating more symptoms and tiredness, respectively. A recent systematic review recommended ThyPRO as the preferred measurement tool for the assessment of health-related quality of life in patients with benign thyroid disease. The ThyPRO and other instruments were administered in English, French, German, or Dutch as appropriate. We had initially planned for cardiovascular events and thyroid-specific quality of life to be the two primary outcomes. However, this plan was modified during the trial to thyroid-specific quality of life scores as the two primary outcomes and cardiovascular events as a secondary outcome when it became apparent that the trial would be underpowered for cardiovascular events owing to delays and difficulties in recruitment.

The secondary outcomes included changes from baseline in generic health-related quality of life (as assessed by the EuroQoL [EQ] Group 5-Dimension Self-Report Questionnaire [EQ-5D]; scores on the EQ-5D descriptive index range from −0.59 to 1.00, and scores on the EQ visual-analogue scale range from 0 to 100, with higher scores indicating better quality of life), comprehensive thyroid-related quality of life (as assessed by the ThyPRO-39 score, a shorter version of the ThyPRO measure, at final follow-up only), handgrip strength (as assessed by means of the Jamar isometric dynamometer, with the recorded score as the best of three measures in the dominant hand), executive cognitive function (as assessed with the letter–digit coding test, which indicates the speed of processing according to the number of correct responses in matching nine letters with nine digits in 90 seconds; minimum score, 0, with higher scores indicating better executive cognitive function; there is no maximum score), blood pressure (systolic and diastolic), weight, body-mass index, waist circumference, activities of daily living (as assessed by the Barthel Index of functional levels in activities of daily living, on a scale ranging from 0 to 20, with higher scores indicating better performance), the Instrumental Activities of Daily Living score (on a scale from 0 to 14, with higher scores indicating better performance in activities of daily living), and fatal and nonfatal cardiovascular events. The minimum follow-up was 1 year, and the maximum follow-up was 3 years.

**SAFETY AND RECORDING OF ADVERSE EVENTS**

Adverse events were assessed, managed, recorded, reported, and analyzed in accordance with the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended). Adverse events of special interest included new atrial fibrillation, heart failure, fracture, and new diagnosis of osteoporosis. The score on the ThyPRO Hypothyroid Symptoms scale was recorded as a measure of possible adverse effects (on a scale from 0 to 100, with higher scores indicating more symptoms; minimum clinically important difference has been estimated as 9 points).

**STATISTICAL ANALYSIS**

The Hypothyroid Symptoms and Tiredness scores from the ThyPRO were the two primary outcomes, with the required P value for statistical significance split equally to each test (0.05/2 = 0.025 for each test). We assumed standard deviations for data at 1 year of 13.3 and 18.3 on the 100-point scales, respectively, after adjustment for baseline values. These calculations provided the trial with 80% power to detect a change with levothyroxine treatment (vs. placebo) of 3.0 points on the Hypothyroid Symptoms score and 4.1 points on the Tiredness score with our revised maximum expected number of recruited participants of 750, and with changes of 3.5 points and 4.9 points, respectively, with our minimum expected number of 540 participants. Justification for these power calculations is provided in the trial protocol.

The methods of analysis of the continuous efficacy outcomes involving measurements at baseline and follow-up were analyzed at each time point for the comparison of the two trial groups, with adjustment for stratification variables (country, sex, and starting dose of levothyroxine) and baseline levels of the same variable with the use of multivariate linear regression (see the Supplementary Appendix). The efficacy and safety analyses were carried out in a modified intention-to-treat population, which included participants with data on the outcome of interest. Patients who discontinued the trial regimen...
continued to be followed for the modified intention-to-treat analysis. These analyses were supported with sensitivity analyses that used mixed-effects models and multiple imputations for missing data. The primary and secondary outcomes at 12 months were also analyzed in pre-specified subgroups according to sex and baseline thyrotropin level. Analyses were repeated in the per-protocol population, which included participants who continued to take the trial regimen per the trial protocol.

**RESULTS**

**TRIAL POPULATION**

We screened 2647 community-dwelling persons who were at least 65 years of age and who were identified as having biochemical subclinical hypothyroidism. A total of 737 participants underwent randomization, 369 of whom were assigned to receive placebo and 368 to receive levothyroxine (Fig. 1). The characteristics at baseline were similar in the two groups (Table 1, and Table S1 in the Supplementary Appendix). The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women. A score of 0 (indicating no symptoms) at baseline was observed in 199 of 737 participants (27.0%) on the Hypothyroid Symptoms scale and in 64 (8.7%) on the Tiredness scale; 36 participants (4.9%) had a score of 0 in both domains.

A total of 337 participants (91.3%) who were randomly assigned to the placebo group completed 12-month follow-up, as did 332 (90.2%) in the levothyroxine group. The median follow-up for all the participants who underwent randomization (including participants who discontinued the trial regimen) was 17.3 months (interquartile range, 12.0 to 24.4) in the placebo group and 18.0 months (interquartile range, 11.0 to 25.4) in the levothyroxine group. The median dose of levothyroxine at 1 year was 50 μg. The numbers of patients who were included in the analyses are presented in Figure 1.

**THYROID-FUNCTION TESTS**

The mean (±SD) thyrotropin level at baseline was 6.40±2.01 mIU per liter. The thyrotropin levels were reduced from baseline to a greater extent in the levothyroxine group than in the placebo group at all time points of review, with a mean between-group difference of 2.29 mIU per liter at 6 to 8 weeks after randomization (P<0.001) (Table S2 in the Supplementary Appendix). At 12 months, the mean thyrotropin level was 5.48±2.48 mIU per liter in the placebo group, as compared with 3.63±2.11 mIU per liter in the levothyroxine group, resulting in a between-group difference of 1.92 mIU per liter (P<0.001) (Table 2 and Fig. 2). There was a significant interaction between the trial group and the office visit (P=0.03), with a reduction in the thyrotropin level being the greatest at 6 to 8 weeks.

**Figure 1. Randomization, Follow-up, and Dose Levels.** Exclusions for other reasons included use of antithyroid medication (in 17 persons), recent thyroid surgery (in 1), recent acute coronary syndrome (in 1), current participation in another trial (in 1), and adrenal insufficiency (in 1). Two patients who were excluded because the thyrotropin level reverted to less than 4.60 mIU per liter also had an additional exclusion of galactose intolerance. Extended follow-up beyond 12 months was conducted in a subgroup of patients, with a median duration of follow-up from baseline of 24.2 months (interquartile range, 18.4 to 30.3) in the placebo group and 24.5 months (interquartile range, 18.4 to 30.5) in the levothyroxine group.
Free thyroxine levels were not routinely measured, although the data were available in a subgroup of patients. The mean free thyroxine level was 2.3 pmol per liter (0.2 ng per deciliter) higher in the levothyroxine group than in the placebo group both at 6 to 8 weeks and at 12 months (P<0.001 for both comparisons) (Table S3 in the Supplementary Appendix).

**Thyroid-Specific Quality of Life**

The mean Hypothyroid Symptoms score at 12 months (with adjustment for baseline score) was 16.7±17.5 in the placebo group and 16.6±16.9 in the levothyroxine group (P=0.99). The mean Tiredness score was 28.6±19.5 in the placebo group and 28.7±20.2 in the levothyroxine group (P=0.77). We found no differences in the mean change at 1 year in the Hypothyroid Symptoms score (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group) or the Tiredness score (3.2±17.7 and 3.8±18.4, respectively) (Table 2). There were no significant between-group differences in either of these measures at 6 to 8 weeks (Table S4 in the Supplementary Appendix). There was a small-magnitude between-group difference in the Tiredness score, with a lower value in the levothyroxine group than in the placebo group (difference, −3.49; P=0.05) at the extended fol-

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo Group</th>
<th>Levothyroxine Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age — yr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>74.8±6.8</td>
<td>74.0±5.8</td>
</tr>
<tr>
<td>Range</td>
<td>65.1–93.4</td>
<td>65.2–93.0</td>
</tr>
<tr>
<td>Female sex — no. (%)</td>
<td>198 (53.7)</td>
<td>198 (53.8)</td>
</tr>
<tr>
<td>White race — no. (%)†</td>
<td>362 (98.1)</td>
<td>362 (98.4)</td>
</tr>
<tr>
<td>Standard housing — no. (%)‡</td>
<td>356 (96.5)</td>
<td>358 (97.3)</td>
</tr>
<tr>
<td>Thyrotropin — mIU/liter</td>
<td>6.38±2.01</td>
<td>6.41±2.01</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>5.76 (5.10–6.94)</td>
<td>5.73 (5.12–6.83)</td>
</tr>
<tr>
<td>Range</td>
<td>4.60–17.60</td>
<td>4.60–17.60</td>
</tr>
<tr>
<td>Free thyroxine — pmol/liter‖</td>
<td>13.3±1.9</td>
<td>13.4±2.1</td>
</tr>
<tr>
<td>Hypothyroid Symptoms score</td>
<td>16.9±17.9</td>
<td>17.5±18.8</td>
</tr>
<tr>
<td>Tiredness score</td>
<td>25.5±20.3</td>
<td>25.9±20.6</td>
</tr>
<tr>
<td>Blood pressure — mm Hg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>140.4±18.9</td>
<td>141.2±18.7</td>
</tr>
<tr>
<td>Diastolic</td>
<td>74.8±11.7</td>
<td>74.1±11.6</td>
</tr>
<tr>
<td>Body-mass index</td>
<td>27.7±4.6</td>
<td>28.1±5.3</td>
</tr>
</tbody>
</table>
low-up review (Table 2). Prespecified analyses according to sex and baseline thyrotropin level did not reveal any subgroups of patients who benefited from treatment with levothyroxine. Per-protocol analyses and sensitivity analyses with the use of multiple imputation of missing values showed no significant differences between the levothyroxine group and the placebo group (Tables S4 and S5 in the Supplementary Appendix).

**OTHER OUTCOME MEASURES**

The EQ-5D descriptive index showed a small deterioration at 12 months (mean difference between the levothyroxine group and the placebo group, −0.025; P=0.05) but a minor improvement at extended follow-up (mean difference, 0.040; P=0.03); there were no significant between-group differences at 6 to 8 weeks. There were no significant between-group differences in the score on the EQ visual-analogue scale (Table 2, and Table S2 in the Supplementary Appendix).

No significant effects were seen in any of the other secondary-outcome measures, either in the modified intention-to-treat or per-protocol analyses or in the prespecified subgroups (Table 2, and Tables S4, S6, S7, and S8 in the Supplementary Appendix). Results regarding cardiovascular events and total and cardiovascular mortality are provided in Table 3 and in Figures S1 and S2 in the Supplementary Appendix.

**ADVERSE EFFECTS AND EVENTS**

We found no significant difference in the Hypothyroid Symptoms score (according to the ThyPRO assessment) with levothyroxine, as compared with placebo, at any time point (Table 2, and Table S2 in the Supplementary Appendix). The incidence of serious adverse events of special interest (atrial fibrillation, heart failure, fracture, or new diagnosis of osteoporosis) was similar in the two groups (Table 3). The number of patients with at least one serious adverse event was slightly higher in the placebo group than in the levothyroxine group (P=0.049), as was the total number of serious adverse events. However, we observed no pattern of event type that contributed to this difference. The proportions of patients who discontinued the trial regimen or who withdrew from follow-up were similar in the two groups (Table 3).

**DISCUSSION**

In this multicenter, double-blind, randomized, placebo-controlled, parallel-group trial involving
Table 2. Outcomes at 12 Months and Extended Follow-up.*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>At 12 Mo</th>
<th>Difference (95% CI)</th>
<th>P Value</th>
<th>At Extended Follow-up Visit†</th>
<th>Difference (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (N = 369)</td>
<td>Levothyroxine (N = 368)</td>
<td>Placebo (N = 320)</td>
<td>Levothyroxine (N = 318)</td>
<td></td>
<td>Placebo (N = 187)</td>
<td>Levothyroxine (N = 194)</td>
<td></td>
</tr>
<tr>
<td>Thyrotropin — mIU/liter</td>
<td>6.38±2.01 (5.10 to 6.94)</td>
<td>6.41±2.01 (5.12 to 6.83)</td>
<td>5.48±2.48 (3.91 to 6.46)</td>
<td>3.63±2.11 (2.45 to 4.22)</td>
<td>−1.92 (−2.24 to −1.59)</td>
<td>&lt;0.001</td>
<td>5.28±2.50 (3.78 to 6.26)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>5.76</td>
<td>5.70</td>
<td>4.90</td>
<td>3.16</td>
<td>—</td>
<td>—</td>
<td>4.94</td>
</tr>
<tr>
<td>Primary outcomes‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypothyroid Symptoms score</td>
<td>16.9±17.9</td>
<td>17.5±18.8</td>
<td>16.7±17.5</td>
<td>16.6±16.9</td>
<td>0.0</td>
<td>(−2.0 to 2.1)</td>
<td>0.99</td>
</tr>
<tr>
<td>Tiredness score</td>
<td>25.5±20.3</td>
<td>25.9±20.6</td>
<td>28.6±19.5</td>
<td>28.7±20.2</td>
<td>0.4</td>
<td>(−2.1 to 2.9)</td>
<td>0.77</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQ-5D descriptive score</td>
<td>0.847±0.171</td>
<td>0.846±0.187</td>
<td>0.853±0.191</td>
<td>0.833±0.212</td>
<td>−0.025</td>
<td>(−0.050 to 0.000)</td>
<td>0.05</td>
</tr>
<tr>
<td>EQ VAS score</td>
<td>76.5±16.3</td>
<td>78.4±15.3</td>
<td>77.4±13.7</td>
<td>77.3±15.6</td>
<td>−1.3</td>
<td>(−3.2 to 0.6)</td>
<td>0.18</td>
</tr>
<tr>
<td>Hand-grip strength — kg</td>
<td>27.5±11.3</td>
<td>28.0±10.2</td>
<td>27.1±11.2</td>
<td>27.5±10.5</td>
<td>−0.1</td>
<td>(−0.9 to 0.7)</td>
<td>0.84</td>
</tr>
<tr>
<td>Blood pressure — mm Hg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>140.4±18.9</td>
<td>141.2±18.7</td>
<td>138.4±17.8</td>
<td>138.3±18.7</td>
<td>0.1</td>
<td>(−2.1 to 2.4)</td>
<td>0.90</td>
</tr>
<tr>
<td>Diastolic</td>
<td>74.8±11.7</td>
<td>74.1±11.6</td>
<td>73.5±11.1</td>
<td>72.8±11.4</td>
<td>−0.1</td>
<td>(−1.5 to 1.3)</td>
<td>0.93</td>
</tr>
<tr>
<td>Body-mass index</td>
<td>27.7±4.6</td>
<td>28.1±5.3</td>
<td>27.7±4.6</td>
<td>27.9±5.1</td>
<td>0.0</td>
<td>(−0.2 to 0.2)</td>
<td>0.89</td>
</tr>
<tr>
<td>Waist circumference — cm</td>
<td>97.5±12.8</td>
<td>98.5±13.6</td>
<td>96.8±13.1</td>
<td>98.0±13.2</td>
<td>0.4</td>
<td>(−0.4 to 1.3)</td>
<td>0.34</td>
</tr>
<tr>
<td>Adverse symptom assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperthyroid Symptoms score§</td>
<td>10.5±11.2</td>
<td>10.5±11.2</td>
<td>10.3±11.3</td>
<td>10.5±10.8</td>
<td>0.6</td>
<td>(−0.7 to 1.9)</td>
<td>0.35</td>
</tr>
</tbody>
</table>
older participants with subclinical hypothyroidism, treatment with levothyroxine was associated with a persistently lower serum thyrotropin level than was placebo (between-group difference, approximately 2 mIU per liter), with the maximum effects seen at time of first review (6 to 8 weeks). We found that levothyroxine had no consistent beneficial effect on thyroid-related symptoms. This finding was true in both older men and older women and for different thyrotropin levels at baseline. Our trial had good statistical power to detect a clinically meaningful effect on thyroid-related quality of life, with 95% confidence intervals that excluded a beneficial effect greater than 2.1 points (on a scale from 0 to 100) in either of the two primary outcomes. If a symptom benefit was to have occurred, it would have been expected to be seen at 12 months.

The subsequent small-magnitude between-group difference in tiredness with levothyroxine versus placebo in the subgroup of patients who had extended follow-up is likely to be a chance finding. In contrast, an observational study of the treatment of autoimmune hypothyroidism in middle-age participants (median baseline thyrotropin level, 8.1 mIU per liter) showed that the Tiredness score improved markedly (reduction of 12 points at 6 months) and that the Hypothyroid Symptoms score also was reduced (by 2 points). A small reduction in tiredness has previously been shown in a short-term trial of levothyroxine for the treatment of subclinical hypothyroidism in 120 middle-age participants. There are limited data from high-quality, randomized, controlled trials regarding the effects of levothyroxine replacement in older persons with subclinical hypothyroidism. Studies have generally been small (≤120 participants) and underpowered, often focusing on younger participants and with a short duration of follow-up.

Levothyroxine treatment yielded no significant beneficial effects on a range of secondary-outcome measures. We found a slight deterioration (of borderline statistical significance) in the EQ-5D descriptive index with levothyroxine versus placebo at 12 months but an improvement versus placebo in the subgroup of patients who completed extended follow-up (median, 24.5 months). The effects we observed were in opposite directions at these different time points and were of very small magnitude (−0.025 at 12 months and 0.040 at extended follow-up), and therefore these
are likely to be random chance findings. The estimated minimally important difference in the EQ-5D descriptive index that has been reported in a recent review as being between 0.037 and 0.069. No effect of treatment was seen with regard to the EQ-5D descriptive index that has been reported in a recent review as being between 0.037 and 0.069.24 No evidence of any association of increased risk of adverse events.26

The new england journal of medicine

Many older persons with biochemical results that are consistent with subclinical hypothyroidism will have resolution to a euthyroid state if they are followed up without treatment. In total, approximately three out of five persons that we screened for entry into the trial on the basis of previously elevated thyrotropin levels had resolution to normal thyroid biochemical results and were therefore excluded from the trial. These data are consistent with several other observational and trial cohorts that showed a high proportion of participants with an elevated thyrotropin level having resolution to biochemical euthyroidism during follow-up.4,27,28

Our trial has certain strengths. The trial included a sufficient number of participants to provide good statistical power to show no benefits regarding symptoms. We used validated measures of thyroid-specific quality of life that have been shown to be sensitive to change,14,17 as well as a range of secondary outcomes of clinical relevance. However, the trial also had certain limitations. First, we chose to set a thyrotropin target of 0.40 to 4.60 mIU per liter with levothyroxine treatment, which is an approach that reflects recent guidelines, particularly for older persons.7 However, some authorities have recommended a lower thyrotropin target (e.g., 0.40 to 2.50 mIU per liter).29 We cannot exclude the possibility that this more aggressive treatment approach might be beneficial. Second, since few participants had a baseline thyrotropin level of more than 10 mIU per liter, we cannot address whether there are benefits from treatment in this subgroup. Third, the symptom levels at trial entry were low, so we

![Figure 2. Thyrotropin Levels in the Placebo Group and Levothyroxine Group.](https://example.com/figure2.png)

Shown are the results of a modified intention-to-treat analysis. Data are means, and error bars indicate 95% confidence intervals. Extended follow-up beyond 12 months was conducted in a subgroup of patients, with a median duration of follow-up from baseline of 24.2 months (interquartile range, 18.4 to 30.3) in the placebo group and 24.5 months (interquartile range, 18.4 to 30.5) in the levothyroxine group. P<0.001 for between-group differences in the thyrotropin level at 6 to 8 weeks, 12 months, and extended follow-up. Analyses were adjusted for stratification variables (country, sex, and starting dose of levothyroxine) and baseline thyrotropin level with the use of linear regression; data for the extended follow-up visit were additionally adjusted for time to visit.
In conclusion, this trial indicated that treatment with levothyroxine in older persons with subclinical hypothyroidism provided no symptomatic benefits.

In conclusion, this trial indicated that treatment with levothyroxine in older persons with subclinical hypothyroidism provided no symptomatic benefits.

The authors’ full names and academic degrees are as follows: David J. Stott, M.B., Ch.B., M.D., Nicolas Rodondi, M.D., Patricia M. Kearney, M.D., Ph.D., Ian Ford, Ph.D., Rudolf G.J. Westendorp, M.D., Ph.D., Simon P. Mooijaart, M.D., Ph.D., Naveed Sattar, F.Med.Sci., Carole E. Aubert, M.D., Drahomir Aujesky, M.D., Douglas C. Bauer, M.D., Christine Baumgartner, M.D., Manuel R. Blum, M.D., John P. Browne, Ph.D., Stephen Byrne, Ph.D., Tinh-Hai Collet, M.D., Olaf M. Dekkers, M.D., Ph.D., Wendy P.J. den Elzen, Ph.D., Robert S. Du Puy, M.D., Graham Ellis, M.D., Martin Feller, M.D., Carmen Floriani, M.D., Kirsty Hendry, Ph.D., Caroline Hurley, M.P.H., J. Wouter Jukema, M.D., Ph.D., Sharon Kean, Maria Kelly, M.Pharm., Danielle Krebs, Ph.D., Peter Langhorne, M.D., Ph.D., Gemma McCarthy, M.P.H., Vera McCarthy, Ph.D., Alex McConnachie, Ph.D., Mairi McDade, B.Sc., R.G.N., Martina Messow, Ph.D., Annemarie O’Flynn, Ph.D., David O’Riordan, M.Pharm., Rosalinde K.E. Poortvliet, M.D., Ph.D., Terence J Quinn, M.D., Ph.D., Audrey Gemma McCarthy, M.P.H., Vera McCarthy, Ph.D., Alex McConnachie, Ph.D., Mairi McDade, B.Sc., R.G.N., Martina Messow, Ph.D., Annemarie O’Flynn, Ph.D., David O’Riordan, M.Pharm., Rosalinde K.E. Poortvliet, M.D., Ph.D., Terence J Quinn, M.D., Ph.D., Audrey

APPENDIX

The New England Journal of Medicine
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on August 2, 2018. For personal use only. No other uses without permission. Copyright © 2017 Massachusetts Medical Society. All rights reserved.
THYROID HORMONE IN SUBCLINICAL HYPOTHYROIDISM

Russo, M.M.Sc., Carol Sinnott, Ph.D., Jan W.A. Smit, M.D., Ph.D., H. Anette Van Dorland, Ph.D., Kieran A. Walsh, M.Pharm., Elaine K. Walsh, M.B., B.Ch., B.A.O., Torquil Watt, M.D., Robbie Wilson, M.Sc., and Jacobijn Gussekloo, M.D., Ph.D.

The authors’ affiliations are as follows: the Academic Section of Geriatric Medicine, Institute of Cardiovascular and Medical Sciences (D.J.S., K.H., P.L., M. McDade, T.J.Q.), the Roberton Centre for Biostatistics, Institute of Health and Wellbeing (J.F., S.K., A.M., M. Messow, R.W.), and the Institute of Cardiovascular and Medical Sciences (N.S.), University of Glasgow, Glasgow, and Care of the Elderly–Rehabilitation, Monklands Hospital, NHS Lanarkshire, Airdrie (G.E.) — all in the United Kingdom; the Department of General Internal Medicine, Inselspital, Bern University Hospital (N.R., C.E.A., D.A., C.B., M.R.R., M.F., C.F., D.K., H.A.V.D.), and the Institute of Primary Health Care (N.R., M.F.), University of Bern, Bern, and the Service of Endocrinology, Diabetes, and Metabolism, University Hospital of Lausanne, Lausanne (T.H.C.) — all in Switzerland; the Department of Epidemiology and Public Health (P.M.K., J.P.B., C.H., G.M., A.O., D.O., C.S., K.A.W., E.K.W.), the Pharmaceutical Care Research Group, School of Pharmacy (S.B., M.K., K.A.W.), the School of Nursing and Midwifery (V.M.), and the Department of General Practice (A.R., E.K.W.), University College Cork, and the Health Research Board Clinical Research Facility, Mercy University Hospital (M.K.) — all in Cork, Ireland; the Department of Public Health and Center for Healthy Aging, University of Copenhagen (R.G.J.W.), and the Department of Medical Endocrinology, Copenhagen University Hospital Righospitalet (T.W.), Copenhagen, and the Department of Medical Endocrinology, University Hospital Herlev, Herlev (T.W.) — all in Denmark; the Departments of Geronomology and Geriatrics (S.P.M.), Internal Medicine (O.M.D.), Clinical Epidemiology (O.M.D.), Clinical Chemistry and Laboratory Medicine (W.P.J.E.), Public Health and Primary Care (R.S.D.P., R.K.E.P., J.G.), and Cardiology (J.W.J.), Leiden University Medical Centre and the Institute for Evidence-based Medicine in Old Age (S.P.M.), Leiden, and Radioband University Medical Center, Nijmegen (J.W.A.S.) — all in the Netherlands; and the Departments of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco, San Francisco (D.C.B.).

REFERENCES


